KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Accumulated Expenses (2016 - 2025)

Boston Scientific's Accumulated Expenses history spans 17 years, with the latest figure at $3.0 billion for Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 168.32% year-over-year to $3.0 billion; the TTM value through Sep 2025 reached $3.0 billion, up 168.32%, while the annual FY2024 figure was $2.8 billion, 4.8% up from the prior year.
  • Accumulated Expenses for Q3 2025 was $3.0 billion at Boston Scientific, up from $927.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $3.0 billion in Q3 2025 and bottomed at $138.0 million in Q4 2021.
  • The 5-year median for Accumulated Expenses is $1.1 billion (2024), against an average of $1.5 billion.
  • The largest annual shift saw Accumulated Expenses crashed 93.72% in 2021 before it skyrocketed 501.45% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $138.0 million in 2021, then surged by 501.45% to $830.0 million in 2022, then soared by 218.8% to $2.6 billion in 2023, then grew by 4.8% to $2.8 billion in 2024, then rose by 7.5% to $3.0 billion in 2025.
  • Per Business Quant, the three most recent readings for BSX's Accumulated Expenses are $3.0 billion (Q3 2025), $927.0 million (Q1 2025), and $2.8 billion (Q4 2024).